Tevogen Bio

Yahoo Finance • 7 days ago

Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO

Vaccine is intended to stimulate T cell responses against targets across the entire genome of the selected virus, similar to company’s lead product candidate TVGN 489, to mitigate the risk posed by mutations.Approach may provide prophylaxi... Full story

Yahoo Finance • 10 days ago

Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel

WARREN, N.J., March 07, 2025 (GLOBE NEWSWIRE) -- Mittul Mehta, Chief Information Officer & Head of Tevogen.AI at Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech comp... Full story

Yahoo Finance • 14 days ago

Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations

Tevogen Bio will receive the remaining $8 million grant, totaling $10 million, from KRHP LLC this quarter, following a positive review of its progress, particularly in Tevogen.AI.Efficient operations with operating expenses of $9.7 million... Full story

Yahoo Finance • 17 days ago

Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy

Tevogen Bio is focused on delivering affordable, safe, and easy-to-administer T cell therapies.The company’s ExacTcell™ technology enabled a proof-of-concept trial with highly positive results, published in Blood Advances.A key step in mak... Full story

Yahoo Finance • 24 days ago

Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned

600% higher market cap per team member when compared to industry average. Source: Mr. Damodaran at the Stern School of Business at NYU.Current ownership breakdown: Insiders 79%; Independent Board Members 1%; Lead Investor 7%; SPAC Sponsor... Full story

Yahoo Finance • last month

Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision

WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, reaffirms his commit... Full story

Yahoo Finance • last month

Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency

WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, shares a summary of the Company’s 2024 financing activity at... Full story

Yahoo Finance • last month

Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity

WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, today issued a statement from its Founder and CEO, Nobel Pea... Full story

Yahoo Finance • last month

Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans

WARREN, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, congratulates Robert... Full story

Yahoo Finance • last month

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

WARREN, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), is a clinical-stage specialty immunotherapy biotech company. As the biopharma industry faces increasing competition fr... Full story

Yahoo Finance • last month

Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology’s Potential as a Scalable Medical Countermeasure

WARREN, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, met the Center for the Biomedical Advanced Research and Deve... Full story

Yahoo Finance • 2 months ago

Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding

The grant funding will further Tevogen Bio’s mission to develop therapies for treatment of cancers and viral infections.Tevogen Bio may also utilize the grant funding to further expand its artificial intelligence effort.This grant is in ad... Full story

Yahoo Finance • 2 months ago

Tevogen Bio CEO Congratulates Lynne Patton on Being Appointed Deputy Assistant to the President and Director of Minority Outreach

WARREN, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Dr. Ryan Saadi, Chairman and founding CEO of Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech, congratulates Lynne Pat... Full story

Yahoo Finance • 2 months ago

Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure

This expansion is in addition to the previously announced Microsoft for Startups program.PredicTcell, Tevogen Bio’s proprietary technology, is designed for predictive, precision T cell target identification. Tevogen Bio is also proactively... Full story

Yahoo Finance • 2 months ago

Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference

WARREN, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Company” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T-cell therapeutics... Full story